NANOFS Stock Overview
Engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nanoform Finland Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €18.36 |
| 52 Week High | €37.50 |
| 52 Week Low | €17.00 |
| Beta | 0.75 |
| 11 Month Change | -6.42% |
| 3 Month Change | -5.17% |
| 1 Year Change | -21.54% |
| 33 Year Change | -77.33% |
| 5 Year Change | n/a |
| Change since IPO | -63.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| NANOFS | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -6.9% | -3.4% | 1.6% |
| 1Y | -21.5% | 71.3% | 21.0% |
Return vs Industry: NANOFS underperformed the Swedish Life Sciences industry which returned 71.3% over the past year.
Return vs Market: NANOFS underperformed the Swedish Market which returned 21% over the past year.
Price Volatility
| NANOFS volatility | |
|---|---|
| NANOFS Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.8% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: NANOFS has not had significant price volatility in the past 3 months.
Volatility Over Time: NANOFS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 174 | Edward Haeggstrom | www.nanoform.com |
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients, as well as designs and develops nanoformed drug substance. It also offers STARMAP, as a secure online portal to perform large numbers of in-silico CESS experiments The company was founded in 2008 and is headquartered in Helsinki, Finland.
Nanoform Finland Oyj Fundamentals Summary
| NANOFS fundamental statistics | |
|---|---|
| Market cap | SEK 1.59b |
| Earnings (TTM) | -SEK 246.17m |
| Revenue (TTM) | SEK 26.08m |
61.0x
P/S Ratio-6.5x
P/E RatioIs NANOFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANOFS income statement (TTM) | |
|---|---|
| Revenue | €2.30m |
| Cost of Revenue | €672.04k |
| Gross Profit | €1.62m |
| Other Expenses | €23.29m |
| Earnings | -€21.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 22, 2024
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 70.72% |
| Net Profit Margin | -943.89% |
| Debt/Equity Ratio | 0% |
How did NANOFS perform over the long term?
See historical performance and comparison